Post menopausal Osteoporosis
Apr 18, 2019
Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal
Amgen reveals the price of EVENITY Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD 1,825 a month, the bone-building drug was approved by the FDA recently for the treatment of Osteoporosis in postmenopausal women and now will be available i...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
